[Stroke and Other Thromboembolic Complications of Atrial Fibrillation. Part II. Prevention With Warfarin].
In part II of a series of papers on epidemiology and drug prevention of stroke and other thromboembolic complications of atrial fibrillation the authors present data on clinical pharmacology of oral anticoagulants as well as discussion of results of randomized studies demonstrating high efficacy of warfarin in primary and secondary prevention of thromboembolism. According to cumulative data of 7 randomized trials average stroke risk lowering in patients with atrial fibrillation associated with the use of warfarin is 62%. Total bleeding rates during treatment with oral anticoagulants fluctuate between 5 and 10%; about half of these bleedings are serious.
Preobrazhenskiĭ
D V
DV
Presidential Medical Center of Russia; ul. Marshala Timoschenko 15, 121356 Moscow, Russia; Medical Center im. Sani Konycogly, Gaziantep (Turkey).
Sidorenko
B A
BA
Kiktev
V G
VG
Batyraliev
T A
TA
Pershukov
I V
IV
D000925:Anticoagulants / Q000008:administration & dosage; D001281:Atrial Fibrillation; D006801:Humans; D020521:Stroke; D013923:Thromboembolism; D014859:Warfarin
D000925:Anticoagulants; D014859:Warfarin